Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Lynparza and Talzenna are targeted therapies known as PARP inhibitors. Both agents have received FDA approval for treating metastatic breast cancer caused by a BRCA mutation. BRACAnalysis CDx—a companion diagnostic test—received approval at the same time as the agents. The National Comprehensive Cancer Network (NCCN) has added both agents as a preferred single agent treatment for people with advanced breast cancer and a BRCA mutation.
Research is now also looking at PARP inhibitor effectiveness in additional settings including:
You can look for research studies enrolling patients with breast cancer by visiting FORCE's Research Study Search Tool.
Updated 03/25/2019
I need to learn more about genetic testing for hereditary cancer
I have a mutation and cancer. What do I do?
I have a mutation but do not have cancer. What do I do?
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
info@facingourrisk.org
Website by Rareheron Web Design